4月1日，戴维医疗今日收盘12.77元，上涨3.40%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到41.73倍，总市值36.78亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入4.03亿元，同比-12.21%；净利润6330.79万元， 同比-48.44%，销售毛利率56.78%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)81戴维医疗41.7324.923.1336.78亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1硕世生物-1956.94-1956.941.2340.43亿2诺唯 赞-583.67-583.672.5299.23亿3博晖创新-305.50-188.093.3746.89亿4康泰医学-294.1934.523.0157.22亿5华 大基因-216.51236.822.24220.01亿6奥精医疗-121.42-121.421.5522.00亿7睿昂基因-83.80-83.801.3012.12亿 8热景生物-57.27-57.273.15102.65亿9华大智造-54.80-54.804.11 ...

Core Viewpoint - David Medical's stock closed at 12.39 yuan, down 2.21%, with a rolling PE ratio of 40.49 times and a total market value of 3.568 billion yuan, indicating a relatively high valuation compared to the industry average [1] Company Overview - Ningbo David Medical Equipment Co., Ltd. specializes in obstetric and pediatric care equipment and minimally invasive surgical instruments, with key products including infant incubators, radiant warmers, jaundice treatment devices, jaundice detection devices, and minimally invasive surgical instruments [1] - The company has been recognized as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology and is one of the first in the industry to obtain CMDC and CE certifications [1] - David Medical has received multiple awards for its products at domestic and international exhibitions, with several technologies being industry-leading or first in the country [1] Financial Performance - For the third quarter of 2024, the company reported operating revenue of 403 million yuan, a year-on-year decrease of 12.21%, and a net profit of 63.31 million yuan, down 48.44% year-on-year, with a gross profit margin of 56.78% [1] Industry Comparison - The average PE ratio for the medical device industry is 45.22 times, with a median of 32.57 times, positioning David Medical at the 81st rank within the industry [2] - The company's static PE ratio is 24.17 times, and its price-to-book ratio is 3.04 [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a decline in stock price and profitability [1][2] - As of March 26, David Medical's stock closed at 12.68 yuan, down 1.25%, with a rolling price-to-earnings (PE) ratio of 41.44 times and a total market capitalization of 3.652 billion yuan [1] - The company ranks 82nd in the medical device industry, which has an average PE ratio of 45.14 times and a median of 31.99 times [1][2] Group 2 - For the third quarter of 2024, David Medical reported an operating income of 403 million yuan, a year-on-year decrease of 12.21%, and a net profit of 63.31 million yuan, down 48.44% year-on-year [2] - The company's sales gross margin stands at 56.78% [2] - David Medical specializes in obstetric and neonatal care equipment and minimally invasive surgical instruments, with key products including incubators and jaundice treatment devices [1]

戴维医疗收盘下跌2.41%，滚动市盈率41.02倍，总 市值36.14亿元 最新一期业绩显示，2024年三季报，公司实现营业收入4.03亿元，同比-12.21%；净利润6330.79万元， 同比-48.44%，销售毛利率56.78%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)83戴维医疗41.0224.493.0836.14亿行业平均 44.6149.194.84107.27亿行业中值31.8030.552.4747.66亿1硕世生物-1931.98-1931.981.2139.91亿2诺唯 赞-533.38-533.382.3090.68亿3利德曼-354.16169.901.5026.06亿4博晖创新-294.32-181.213.2445.17亿5康泰 医学-285.9333.552.9255.61亿6华大基因-223.96244.972.32227.58亿7奥精医疗-119.40-119.401.5221.63亿8 睿昂基因-82.41-82.411.2811.92亿9华大智造-54.96-54.964.12329.26亿10中红医疗-53.53-36.420.8547.66亿 11天智 ...